Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen

Pan Yue
January 15, 2018 — 13:25 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China chinese finance guangdong healthcare insurance medicine Northern Light pharmaceutical Private Equity Renminbi shenzhen Shenzhen capital group Suzhou venture capital Zelgen

Related News:

China’s Nvidia Contender Cambricon Tech Struggles To Push Chinese-Made AI Chips as It Marks 7th Consecutive Year of Losses

February 9, 2024 — 10:25

ByteDance Is Undervalued: TikTok’s Parent Could Be Worth More Than Tencent and Possibly Meta

January 11, 2024 — 01:33

China To Expand Investment Scope for Its National Social Security Fund

December 8, 2023 — 00:03

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

DealShot: 14 Deals Eclipsing $800 Million With CICC Capital, Shenzhen Capital Group And More

September 28, 2022 — 16:54

US’s Top 10 Public Companies Worth Over Five Times Than China’s Top 10

December 21, 2021 — 23:37

China Tech Digest: Tencent Unveils Three Self-developed Chips; Huawei’s Autonomous Driving Unit Founder Joins Zeekr

November 4, 2021 — 09:39

Franchising and Licensing Asia (FLAsia) 2024